Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2015

Open Access 01-12-2015 | Preliminary research

Rapid kit-based 68Ga-labelling and PET imaging with THP-Tyr3-octreotate: a preliminary comparison with DOTA-Tyr3-octreotate

Authors: Michelle T. Ma, Carleen Cullinane, Kelly Waldeck, Peter Roselt, Rodney J. Hicks, Philip J. Blower

Published in: EJNMMI Research | Issue 1/2015

Login to get access

Abstract

Background

Ge/68Ga generators provide an inexpensive source of a PET isotope to hospitals without cyclotron facilities. The development of new 68Ga-based molecular imaging agents and subsequent clinical translation would be greatly facilitated by simplification of radiochemical syntheses. We report the properties of a tris(hydroxypyridinone) conjugate of the SSTR2-targeted peptide, Tyr3-octreotate (TATE), and compare the 68Ga-labelling and biodistribution of [68Ga(THP-TATE)] with the clinical radiopharmaceutical [68Ga(DOTATATE)].

Methods

A tris(hydroxypyridinone) with a pendant isothiocyanate group was conjugated to the primary amine terminus of H2N-PEG2-Lys(iv-Dde)5-TATE, and the resulting conjugate was deprotected to provide THP-TATE. THP-TATE was radiolabelled with 68Ga3+ from a 68Ge/68Ga generator. In vitro uptake was assessed in SSTR2-positive 427-7 cells and SSTR2-negative 427 (parental) cells. Biodistribution of [68Ga(THP-TATE)] was compared with that of [68Ga(DOTATATE)] in Balb/c nude mice bearing SSTR2-positive AR42J tumours. PET scans were obtained 1 h post-injection, after which animals were euthanised and tissues/organs harvested and counted.

Results

[68Ga(THP-TATE)] was radiolabelled and formulated rapidly in <2 min, in ≥95 % radiochemical yield at pH 5–6.5 and specific activities of 60–80 MBq nmol−1 at ambient temperature. [68Ga(THP-TATE)] was rapidly internalised into SSTR2-positive cells, but not SSTR2-negative cells, and receptor binding and internalisation were specific. Animals administered [68Ga(THP-TATE)] demonstrated comparable SSTR2-positive tumour activity (11.5 ± 0.6 %ID g−1) compared to animals administered [68Ga(DOTATATE)] (14.4 ± 0.8 %ID g−1). Co-administration of unconjugated Tyr3-octreotate effectively blocked tumour accumulation of [68Ga(THP-TATE)] (2.7 ± 0.6 %ID g−1). Blood clearance of [68Ga(THP-TATE)] was rapid and excretion was predominantly renal, although compared to [68Ga(DOTATATE)], [68Ga(THP-TATE)] exhibited comparatively longer kidney retention.

Conclusions

Radiochemical synthesis of [68Ga(THP-TATE)] is significantly faster, proceeds under milder conditions, and requires less manipulation than that of [68Ga(DOTATATE)]. A 68Ga-labelled tris(hydroxypyridinone) conjugate of Tyr3-octreotate demonstrates specificity and targeting affinity for SSTR2 receptors, with comparable in vivo targeting affinity to the clinical PET tracer, [68Ga(DOTATATE)]. Thus, peptide conjugates based on tris(hydroxypyridinones) are conducive to translation to kit-based preparation of PET tracers, enabling the expansion and adoption of 68Ga PET in hospitals and imaging centres without the need for costly automated synthesis modules.
Literature
1.
Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012;56(1):40–7.CrossRefPubMed
2.
Ambrosini V, Campana D, Tomassetti P, Fanti S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. 2012;39(S1):S52–60.CrossRefPubMed
3.
Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51(6):875–82.CrossRefPubMed
4.
Haug AR, Auernhammer CJ, Waengler B, Schmidt GP, Uebleis C, Goeke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349–56.CrossRefPubMed
5.
Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37(1):49–57.CrossRefPubMed
6.
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.PubMedCentralCrossRefPubMed
7.
Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, Schmieder K, Eisenhut M, Haberkorn U, et al. Pharmacokinetic studies of 68Ga-labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. Clin Nucl Med. 2011;36(2):101–8.CrossRefPubMed
8.
Eriksson O, Velikyan I, Selvaraju RK, Kandeel F, Johansson L, Antoni G, et al. Detection of metastatic insulinoma by positron emission tomography with [68Ga]exendin-4—a case report. J Clin Endocrinol Metab. 2014;99(5):1519–24.PubMedCentralCrossRefPubMed
9.
Baum RP, Kulkarni HR. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy—the Bad Berka experience. Theranostics. 2012;2(5):437–47.PubMedCentralCrossRefPubMed
10.
11.
Velikyan I, Beyer GJ, Langstroem B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjugate Chem. 2004;15(3):554–60.CrossRef
12.
Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of 68Ga-labeled peptides. Nucl Med Commun. 2007;28(11):870–5.CrossRefPubMed
13.
Ocak M, Antretter M, Knopp R, Kunkel F, Petrik M, Bergisadi N, et al. Full automation of 68Ga labelling of DOTA-peptides including cation exchange prepurification. Appl Radiat Isot. 2010;68(2):297–302.CrossRefPubMed
14.
Petrik M, Knetsch Peter A, Knopp R, Imperato G, Ocak M, von Guggenberg E, et al. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. Nucl Med Commun. 2011;32(10):887–95.CrossRefPubMed
15.
De Decker M, Turner JH. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm. 2012;27(1):72–6.CrossRefPubMed
16.
Eppard E, Wuttke M, Nicodemus PL, Roesch F. Ethanol-based post-processing of generator-derived 68Ga toward kit-type preparation of 68Ga-radiopharmaceuticals. J Nucl Med. 2014;55(6):1023–8.CrossRefPubMed
17.
Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48(10):1741–8.CrossRefPubMed
18.
Mueller D, Klette I, Baum RP, Gottschaldt M, Schultz MK, Breeman WAP. Simplified NaCl based 68Ga concentration and labeling procedure for rapid synthesis of 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjugate Chem. 2012;23(8):1712–7.CrossRef
19.
Velikyan I, Maecke H, Langstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjugate Chem. 2008;19(2):569–73.CrossRef
20.
Eisenwiener K-P, Prata MIM, Buschmann I, Zhang H-W, Santos AC, Wenger S, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with 67/68Ga and 111In for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjugate Chem. 2002;13(3):530–41.CrossRef
21.
Liu Z, Niu G, Wang F, Chen X. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2009;36(9):1483–94.CrossRefPubMed
22.
de Sa A, Matias AA, Prata MIM, Geraldes CFGC, Ferreira PMT, Andre JP. Gallium labeled NOTA-based conjugates for peptide receptor-mediated medical imaging. Bioorg Med Chem Lett. 2010;20:7345–8.CrossRefPubMed
23.
Simecek J, Schulz M, Notni J, Plutnar J, Kubicek V, Havlickova J, et al. Complexation of metal ions with TRAP (1,4,7-triazacyclononane phosphinic acid) ligands and 1,4,7-triazacyclononane-1,4,7-triacetic acid: phosphinate-containing ligands as unique chelators for trivalent gallium. Inorg Chem. 2012;51(1):577–90.CrossRefPubMed
24.
Notni J, Simecek J, Wester H-J. Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications. Chem Med Chem. 2014;9(6):1107–15.CrossRefPubMed
25.
Notni J, Simecek J, Hermann P, Wester H-J. TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chem Eur J. 2011;17(52):14718–22.CrossRefPubMed
26.
Simecek J, Notni J, Kapp TG, Kessler H, Wester H-J. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of 68Ga-NOPO-c(RGDfK). Mol Pharmaceutics. 2014;11(5):1687–95.CrossRef
27.
Ma MT, Neels OC, Denoyer D, Roselt P, Karas JA, Scanlon DB, et al. Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging. Bioconjugate Chem. 2011;22(10):2093–103.CrossRef
28.
Eder M, Schaefer M, Bauder-Wuest U, Hull W-E, Waengler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjugate Chem. 2012;23(4):688–97.CrossRef
29.
Waldron BP, Parker D, Burchardt C, Yufit DS, Zimny M, Roesch F. Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68. Chem Commun. 2013;49(6):579–81.CrossRef
30.
Knetsch PA, Zhai C, Rangger C, Blatzer M, Haas H, Kaeopookum P, et al. [68Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation. Nucl Med Biol. 2015;42(2):115–22.PubMedCentralCrossRefPubMed
31.
Boros E, Ferreira CL, Cawthray JF, Price EW, Patrick BO, Wester DW, et al. Acyclic chelate with ideal properties for 68Ga PET imaging agent elaboration. J Am Chem Soc. 2010;132(44):15726–33.CrossRefPubMed
32.
Boros E, Ferreira CL, Yapp DTT, Gill RK, Price EW, Adam MJ, et al. RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga. Nucl Med Biol. 2012;39(6):785–94.CrossRefPubMed
33.
Ramogida CF, Cawthray JF, Boros E, Ferreira CL, Patrick BO, Adam MJ, et al. H2 CHXdedpa and H4 CHXoctapa-chiral acyclic chelating ligands for 67/68Ga and 111In radiopharmaceuticals. Inorg Chem. 2015;54(4):2017–31.CrossRefPubMed
34.
Berry DJ, Ma Y, Ballinger JR, Tavare R, Koers A, Sunassee K, et al. Efficient bifunctional gallium-68 chelators for positron emission tomography: tris(hydroxypyridinone) ligands. Chem Commun. 2011;47(25):7068–70.CrossRef
35.
Ma MT, Cullinane C, Imberti C, Terry SYA, Roselt P, Hicks Rodney J, Blower PJ. New tris(hydroxypyridinone) bifunctional chelators containing isothiocyanate groups provide a versatile platform for rapid one-step labeling and PET imaging with 68Ga3+. Bioconjugate Chem. in press, DOI: 10.​1021/​acs.​bioconjchem.​5b00335.
36.
Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149–54.CrossRef
37.
Bycroft BW, Chan WC, Chharbra SR, Hone ND. A novel lysine-protecting procedure for continuous flow solid phase synthesis of branched peptides. Chem Commun. 1993;9:778–9.CrossRef
38.
Carpino LA. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. J Am Chem Soc. 1993;115(10):4397–8.CrossRef
39.
Carpino LA, Han GY. 9-Fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. J Am Chem Soc. 1970;92(19):5748–9.CrossRef
40.
Parry JJ, Eiblmaier M, Andrews R, Meyer LA, Higashikubo R, Anderson CJ, et al. Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells. Mol Imaging. 2007;6(1):56–67.PubMed
41.
Paterson BM, Roselt P, Denoyer D, Cullinane C, Binns D, Noonan W, et al. PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. Dalton Trans. 2014;43(3):1386–96.CrossRefPubMed
42.
Schottelius M, Simecek J, Hoffmann F, Willibald M, Schwaiger M, Wester H-J. Twins in spirit—episode I: comparative preclinical evaluation of [68Ga]DOTATATE and [68Ga]HA-DOTATATE. EJNMMI Research. 2015;5(1):1–10.CrossRef
43.
Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci. 2013;34(12):676–88.CrossRefPubMed
44.
Waser B, Tamma M-L, Cescato R, Maeke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50(6):936–41.
45.
Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Nat Acad Sci. 2006;103(44):16436–41.
46.
Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34(7):982–93.CrossRefPubMed
47.
Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmiti JS, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer. 2002;98(6):930–7.CrossRefPubMed
48.
Beauregard J-M, Hofman MS, Kong G, Hicks RJ. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39(1):50–6.CrossRefPubMed
Metadata
Title
Rapid kit-based 68Ga-labelling and PET imaging with THP-Tyr3-octreotate: a preliminary comparison with DOTA-Tyr3-octreotate
Authors
Michelle T. Ma
Carleen Cullinane
Kelly Waldeck
Peter Roselt
Rodney J. Hicks
Philip J. Blower
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2015
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-015-0131-1

Other articles of this Issue 1/2015

EJNMMI Research 1/2015 Go to the issue

Original research

Hybrid PET/optical imaging of integrin αVβ3 receptor expression using a 64Cu-labeled streptavidin/biotin-based dimeric RGD peptide

Original research

Quantifying and correcting for tail vein extravasation in small animal PET scans in cancer research: is there an impact on therapy assessment?

Original research

Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue

Review

Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging

Original research

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice

Original research

99mTc-MDP bone scintigraphy of the hand: comparing the use of novel cadmium zinc telluride (CZT) and routine NaI(Tl) detectors